- Home
- MGIC vs PHAR Comparison
MGIC vs PHAR Comparison
Compare MGIC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGIC | PHAR |
|---|---|---|
| Founded | 1983 | 1988 |
| Country | Israel | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGIC | PHAR |
|---|---|---|
| Price | $22.07 | $16.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $18.00 | ★ $38.00 |
| AVG Volume (30 Days) | 20.8K | ★ 34.2K |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | 0.00 |
| Revenue | ★ $603,216,000.00 | $362,274,000.00 |
| Revenue This Year | $12.87 | $25.19 |
| Revenue Next Year | $6.23 | $4.47 |
| P/E Ratio | ★ $33.38 | $3,082.88 |
| Revenue Growth | 12.65 | ★ 26.78 |
| 52 Week Low | $11.65 | $7.50 |
| 52 Week High | $28.00 | $21.34 |
Technical Indicators
Market Signals| Indicator | MGIC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 40.82 |
| Support Level | $25.60 | $16.30 |
| Resistance Level | $27.11 | $18.03 |
| Average True Range (ATR) | 0.65 | 0.73 |
| MACD | -0.39 | -0.35 |
| Stochastic Oscillator | 21.39 | 9.72 |
Price Performance
Historical ComparisonAbout MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.